Visiodent Integration And Allianz Contract Will Improve Future Profitability In Healthcare Software

AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Published
09 Feb 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
€13.67
23.2% undervalued intrinsic discount
08 Aug
€10.50
Loading
1Y
-17.0%
7D
-3.7%

Author's Valuation

€13.7

23.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 1.54%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 3.41%

AnalystConsensusTarget has decreased revenue growth from 5.2% to 4.3%, increased profit margin from 4.9% to 6.1% and decreased future PE multiple from 7.3x to 5.9x.

Shared on26 Mar 25
Fair value Increased 8.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 5.29%

AnalystConsensusTarget has decreased revenue growth from 5.2% to 3.9%, decreased profit margin from 4.9% to 2.7% and increased future PE multiple from 7.3x to 12.7x.

Shared on12 Mar 25
Fair value Decreased 6.73%